Meeting
2024 ASCO Genitourinary Cancers Symposium
Topological heterogeneity of genomic and immunologic effects from combination immunotherapy treatment in the neoadjuvant setting for renal cell carcinoma (RCC).
Authors
Tyler Alban
Cleveland Clinic Lerner Research Institute, Cleveland, OH
Tyler Alban , Salendra Singh , Paul G. Pavicic Jr., Patricia A. Rayman , Prerana Parthasarathy Bangalore , Amit Rupani , Vladimir Makarov , Christopher Przybycin , Jennifer S. Ko , Venkatesh Krishnamurthi , Steven Campbell , Timothy An-thy Chan , Brian I. Rini , C. Marcela Diaz-Montero , Moshe Chaim Ornstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 454)
DOI
10.1200/JCO.2024.42.4_suppl.454
Abstract #
454
Poster Bd #
J15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
First Author: Yu Fujiwara
Poster
2023 ASCO Annual Meeting
Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.
First Author: Michel Bila
Poster
2023 ASCO Annual Meeting
Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.
First Author: Rachel Minne
Poster
2019 Genitourinary Cancers Symposium
Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).
First Author: Jaleh Fallah